PeptidePedia The community reference

Special:RecentChanges

Change log·7,183 revisions·page 45 of 72

Every change to PeptidePedia Wiki, newest first. N marks a new page, m a minor edit and b an edit by an approved bot. The byte figure is the page size after the edit; the coloured figure is the change. 7,183 changes are logged in total.

7,183Logged changes
598Bot edits
175Page creations
256Active editors

26 April 2025

  1. (diff | hist) m 01:12 Third-party testing 5,770 ±0 Chromatokid (talk | contribs) fix a broken wikilink [rollback]
  2. (diff | hist) 00:45 Retatrutide 5,894 +24 ManualOfStyleMo (talk | contribs) expand §Reported clinical findings [rollback]
  3. (diff | hist) m 00:12 Peptide stability table 4,044 +26 EscalationEira (talk | contribs) expand §Why cross-source comparison is unsafe [rollback]
  4. (diff | hist) 00:08 Prior authorisation 3,226 +132 AnalyticalAnnie (talk | contribs) expand §How it operates [rollback]

25 April 2025

  1. (diff | hist) m 23:26 Survodutide 4,510 +40 TSH_Tallulah (talk | contribs) convert the substitution list to a table so the analogues line up [rollback]
  2. (diff | hist) 15:26 Medutest 3,795 ±0 ColdChainCleo (talk | contribs) ce [rollback]
  3. (diff | hist) 12:29 Insulin secretion 5,969 +527 SerialCommaSeb (talk | contribs) British spelling per PP:MOS [rollback]
  4. (diff | hist) m 10:16 LEADER trial 3,537 ±0 DMF_Dermot (talk | contribs) the percentage quoted was placebo-adjusted; label it [rollback]
  5. (diff | hist) m 06:10 Purity claim inflation 4,595 ±0 BlankVialBo (talk | contribs) expand §What a purity figure does establish [rollback]
  6. (diff | hist) 03:28 Xi'an Mokemei Biotechnology 4,757 +1,687 DiagramDelphine (talk | contribs) add the how-to-request-a-batch-record sentence to §Ordering and availability [rollback]
  7. (diff | hist) m 03:06 Dose escalation schedule 4,073 ±0 SyringeSybille (talk | contribs) expand §Representative schedules [rollback]

24 April 2025

  1. (diff | hist) m 16:14 Methionine oxidation 3,850 +268 SchemaSorcha (talk | contribs) add the ionisation mode to the mass-spectrometry description [rollback]
  2. (diff | hist) 10:57 Talk:ChinaPeptides 1,033 +111 DisambigDenzil (talk | contribs) /* Which name should the article title use? */ reply
  3. (diff | hist) m 09:12 SUSTAIN trial programme 4,187 ±0 StyleSheetSybil (talk | contribs) attribute the subgroup finding as exploratory [rollback]
  4. (diff | hist) m 01:32 Subcutaneous injection 4,081 +42 StubTagTeodor (talk | contribs) state that swirling rather than shaking is the handling convention, sourced [rollback]

23 April 2025

  1. (diff | hist) m 23:11 Contraindications of incretin therapy 4,296 ±0 Chromatokid (talk | contribs) add the medical-disclaimer cross-link [rollback]
  2. (diff | hist) 20:34 Intention-to-treat analysis 3,822 ±0 INN_Ingrid (talk | contribs) split the results table so the two doses are separate rows [rollback]
  3. (diff | hist) 18:59 Sigma-Aldrich (Shanghai) Trading 2,925 +988 BatchNumberBede (talk | contribs) rm the discount code added by an anonymous editor [rollback]
  4. (diff | hist) 16:24 Number needed to treat 3,631 ±0 CounterfeitCato (talk | contribs) the article attributed a finding to the wrong trial in the programme [rollback]
  5. (diff | hist) 14:45 Multi-dose vial 12,489 +1,238 SyringeSybille (talk | contribs) expand §Definition and compendial basis [rollback]
  6. (diff | hist) m 14:16 Repackaging 3,958 ±0 NPOV_Nadia (talk | contribs) add the note that lyophilised material tolerates excursions better than solution [rollback]
  7. (diff | hist) 09:40 Temperature excursion 4,790 +802 CouplingCillian (talk | contribs) add the excursion tolerance with the study it derives from [rollback]
  8. (diff | hist) 09:33 Talk:ChinaPeptides 822 +195 ScopeSeverin (talk | contribs) /* Which name should the article title use? */ reply
  9. (diff | hist) 09:12 Talk:Sigma-Aldrich (Shanghai) Trading 822 +314 AnalyticalAnnie (talk | contribs) /* A distributor that does not claim manufacture, and what the article may infer from that */ reply
  10. (diff | hist) m 06:56 Lixisenatide 3,215 ±0 SemaglutideSasha (talk | contribs) fix the anchor on an internal link [rollback]
  11. (diff | hist) 05:47 Area percent purity 6,569 ±0 DiluentDiya (talk | contribs) state that ultraviolet response is not uniform across impurities [rollback]
  12. (diff | hist) m b 03:19 Sangon Biotech 7,423 +512 ArchiveBot (talk | contribs) bot: add supplier category [rollback]
  13. (diff | hist) 02:29 Cold chain 20,418 ±0 PurityClaimPia (talk | contribs) de-orphan [rollback]
  14. (diff | hist) m 02:11 Active pharmaceutical ingredient 3,553 ±0 TrialsTabitha (talk | contribs) unpipe a link that did not need piping [rollback]

22 April 2025

  1. (diff | hist) 23:33 Dipeptidyl peptidase-4 6,022 ±0 LCellLeif (talk | contribs) ce [rollback]
  2. (diff | hist) 18:19 SURMOUNT trial programme 3,589 +30 ForestPlotFinn (talk | contribs) state that the trial has reported but is not yet peer-reviewed [rollback]
  3. (diff | hist) m b 17:54 Retention time 3,306 ±0 CiteBot (talk | contribs) bot: normalise citation format [rollback]
  4. (diff | hist) 14:16 Talk:ChinaPeptides 611 +259 INN_Ingrid (talk | contribs) /* Which name should the article title use? */ reply
  5. (diff | hist) 11:41 Talk:ChinaPeptides 400 +266 MoveRequestMio (talk | contribs) /* Which name should the article title use? */ new section
  6. (diff | hist) 07:01 Nantong Guangyuan Chemical 10,293 +675 SiteReactionSuz (talk | contribs) serial comma per PP:MOS [rollback]
  7. (diff | hist) m 04:20 Enteroendocrine L cell 4,648 +29 NauseaNoor (talk | contribs) expand §GLP-1 synthesis and secretion [rollback]
  8. (diff | hist) m 02:50 Weight regain after discontinuation 4,031 ±0 FlowTrialFraser (talk | contribs) add the interaction with the mechanism that explains it [rollback]

21 April 2025

  1. (diff | hist) m 21:19 Global access disparity 3,200 +581 AppealsArno (talk | contribs) fix the anchor on an internal link [rollback]
  2. (diff | hist) m b 21:02 Hubei Jianxiang Bioscience 2,874 +701 CiteBot (talk | contribs) bot: normalise citation format [rollback]
  3. (diff | hist) m b 18:47 Analytical method validation 5,053 +611 ArchiveBot (talk | contribs) bot: flag bare reference [rollback]
  4. (diff | hist) m 17:26 Peptide synthesis 4,134 +21 BalanceBirdie (talk | contribs) expand §Why yield falls with length [rollback]
  5. (diff | hist) 14:38 Talk:Sigma-Aldrich (Shanghai) Trading 611 +383 COA_Colwyn (talk | contribs) /* A distributor that does not claim manufacture, and what the article may infer from that */ reply
  6. (diff | hist) 13:28 GLP-1 receptor 6,418 ±0 Retention_Time_Rae (talk | contribs) clarify that the receptor is expressed outside the pancreas [rollback]
  7. (diff | hist) m 10:10 Counterfeit peptide 4,002 +26 AppendixAlva (talk | contribs) clarify that a signature on a certificate is a release, not a verification [rollback]
  8. (diff | hist) 09:31 Dual incretin agonist 4,734 ±0 CuriousCallum (talk | contribs) the lead claimed weekly dosing for a compound dosed daily; corrected [rollback]
  9. (diff | hist) 08:27 Shanghai Wibson Biotechnology 6,412 +29 PanelPlannerPam (talk | contribs) add the note that self-published material is usable only for what it states about itself [rollback]
  10. (diff | hist) m 04:41 Amylin receptor agonist 3,909 ±0 MetricMabel (talk | contribs) expand §Clinical findings [rollback]
  11. (diff | hist) m 03:55 Solid-phase peptide synthesis 5,107 +31 ReceptorRhoda (talk | contribs) state the difference between a validated shipper and an insulated box [rollback]
  12. (diff | hist) m 03:16 Peptide harm reduction 3,468 +30 PatientPanelPru (talk | contribs) attribute the affordability estimate to the analysis it comes from [rollback]
  13. (diff | hist) 00:54 High-performance liquid chromatography 6,047 +36 OralSemaOswin (talk | contribs) fix hyphenation per PP:MOS [rollback]

20 April 2025

  1. (diff | hist) 23:38 Reconstitution calculator 6,229 +222 SPPS_Sorrel (talk | contribs) sentence case in headings per PP:MOS [rollback]
  2. (diff | hist) 22:14 Mass spectrometry 5,248 +25 TFA_Counterion (talk | contribs) typo [rollback]
  3. (diff | hist) 20:42 Bacterial endotoxin test 4,398 ±0 Chromatokid (talk | contribs) add the sample preparation, since the result depends on it [rollback]
  4. (diff | hist) 17:01 Patent expiry and biosimilars 3,580 +369 BiosimilarBoaz (talk | contribs) attribute the compounding statement to the pharmacy board that issued it [rollback]
  5. (diff | hist) 13:25 Incretin effect 5,768 ±0 DMF_Dermot (talk | contribs) de-orphan [rollback]
  6. (diff | hist) 08:46 Cost per milligram 3,122 +121 Chromatokid (talk | contribs) add the note that prices below the list price are not evidence of a counterfeit [rollback]
  7. (diff | hist) 07:28 Good manufacturing practice 3,919 ±0 GMP_Gita (talk | contribs) add the good-manufacturing-practice framework by name [rollback]
  8. (diff | hist) m 06:41 International nonproprietary name 3,183 +38 DulaglutideDug (talk | contribs) rm duplicated pharmacokinetics — the same figures appear in the infobox [rollback]
  9. (diff | hist) N 05:04 Sigma-Aldrich (Shanghai) Trading 1,937 +1,937 BlankVialBo (talk | contribs) new article: supplier organisation, created after the notability discussion

19 April 2025

  1. (diff | hist) 20:19 ChinaPeptides 7,916 +549 MicrodoseMagnus (talk | contribs) rm the discount code added by an anonymous editor [rollback]
  2. (diff | hist) 16:19 Tianjin Finder Chemical 7,633 +771 VerifyFirstVida (talk | contribs) add the registered legal name exactly as it appears in the registry record [rollback]
  3. (diff | hist) 13:12 Melanotan II 3,650 ±0 IpamorelinIsold (talk | contribs) expand §Pharmacology [rollback]
  4. (diff | hist) 12:19 Amylin 4,252 ±0 LipidLedgerLou (talk | contribs) expand §Amyloid formation [rollback]
  5. (diff | hist) 10:53 Grey market 3,184 +579 ForestPlotFinn (talk | contribs) add the customs-detention point as a logistics fact, sourced [rollback]
  6. (diff | hist) 10:05 Talk:Sigma-Aldrich (Shanghai) Trading 400 +613 ScopeSeverin (talk | contribs) /* A distributor that does not claim manufacture, and what the article may infer from that */ new section
  7. (diff | hist) m b 09:06 Sterility testing 3,636 ±0 ArchiveBot (talk | contribs) bot: sort category members [rollback]

18 April 2025

  1. (diff | hist) 23:54 SURPASS trial programme 4,474 +516 AppendixAlva (talk | contribs) expand §The head-to-head comparison [rollback]
  2. (diff | hist) m 23:16 Temperature excursion 3,988 +749 CouplingCillian (talk | contribs) split overlong sentence [rollback]
  3. (diff | hist) m 21:31 Liquid chromatography-mass spectrometry 3,724 ±0 KarlFischerKit (talk | contribs) clarify that area percent is not mass percent [rollback]
  4. (diff | hist) m 19:54 Lot traceability 4,002 ±0 MolarMassMaeve (talk | contribs) clarify that a certificate is a claim by its issuer [rollback]
  5. (diff | hist) 19:17 Reconstitution of lyophilised peptides 5,243 +854 GramsNotUnitsGil (talk | contribs) serial comma per PP:MOS [rollback]
  6. (diff | hist) m 11:10 Insulin syringe 4,667 +556 BacWaterBarnaby (talk | contribs) the rounding in the table lost a decimal place that matters at low doses [rollback]
  7. (diff | hist) 09:01 HOMA-IR 3,431 ±0 GMP_Gita (talk | contribs) rm the claim that the marker predicts outcome; the cited study is cross-sectional [rollback]
  8. (diff | hist) 05:09 Missed dose 4,407 ±0 GMP_Gita (talk | contribs) serial comma per PP:MOS [rollback]
  9. (diff | hist) 03:23 Amino acid analysis 4,038 +335 DiluentDiya (talk | contribs) convert the method-comparison paragraph to a table [rollback]
  10. (diff | hist) m b 00:18 Triple agonist 3,428 ±0 CiteBot (talk | contribs) bot: expand DOI to full citation [rollback]

17 April 2025

  1. (diff | hist) 15:35 Glucagon-like peptide-1 10,252 +13 StopperingSteff (talk | contribs) attribute the gastric-emptying effect to the study that measured it [rollback]
  2. (diff | hist) 15:17 Drug master file 3,312 +132 StateBoardStace (talk | contribs) name the regulator rather than writing "the authorities" [rollback]
  3. (diff | hist) m b 14:58 Baseline laboratory panel 3,526 +487 StubSorterBot (talk | contribs) bot: update parent category chain [rollback]
  4. (diff | hist) m 12:04 Shanghai Sigma-Audley New Material Technology 8,293 +770 BatchNumberBede (talk | contribs) add the note that self-published material is usable only for what it states about itself [rollback]
  5. (diff | hist) 09:42 Beta cell function 4,916 ±0 DefinedTermDov (talk | contribs) add the counter-regulatory glucagon point, sourced [rollback]
  6. (diff | hist) m 07:41 USP General Chapter 71 3,363 ±0 SchematicScout (talk | contribs) add the repeatability figure with the number of injections [rollback]
  7. (diff | hist) m 04:21 GL Biochem (Shanghai) 13,777 +810 PurityClaimPia (talk | contribs) clarify that no manufacturing or marketing authorisation is claimed or established [rollback]
  8. (diff | hist) 02:11 Personal importation policy 3,251 +96 LabelLibby (talk | contribs) add category for drug regulation [rollback]

16 April 2025

  1. (diff | hist) m 22:03 Satiety signalling 4,441 ±0 SatietySunniva (talk | contribs) split overlong sentence [rollback]
  2. (diff | hist) 19:26 Glucose-dependent insulinotropic polypeptide 6,711 +25 ReceptorRhoda (talk | contribs) clarify that the incretin effect is defined by the oral–intravenous comparison [rollback]
  3. (diff | hist) N 09:00 Temperature excursion 3,239 +3,239 SyringeSybille (talk | contribs) create article — process stub
  4. (diff | hist) 08:32 Vial 19,236 +957 DrTitration (talk | contribs) expand §Sealing and capping [rollback]
  5. (diff | hist) m b 07:57 Chain of custody 4,085 ±0 CategoryBot (talk | contribs) bot: flag bare reference [rollback]
  6. (diff | hist) 07:41 MOTS-c 3,310 +62 GHK_Gwendolen (talk | contribs) space between number and unit per PP:MOS [rollback]
  7. (diff | hist) 06:52 ISO 9001 3,340 ±0 TrialsTabitha (talk | contribs) typo [rollback]

15 April 2025

  1. (diff | hist) 19:35 Janoshik Analytical 4,969 +843 LeanMassLars (talk | contribs) add the difference between a batch certificate and a lot-specific one [rollback]
  2. (diff | hist) m 09:13 Resin cleavage 3,277 ±0 SPPS_Sorrel (talk | contribs) give the closure integrity test by name [rollback]
  3. (diff | hist) 09:03 Beyond-use date 13,131 +17 UnitAuditUwe (talk | contribs) correct the needle gauge given for subcutaneous administration [rollback]
  4. (diff | hist) 09:03 Talk:Blind sampling 959 +122 NPOV_Nadia (talk | contribs) /* Selection on the outcome is a third failure, not a footnote */ reply
  5. (diff | hist) 03:03 Research use only 6,689 ±0 API_Aurora (talk | contribs) expand §What the category excludes [rollback]

14 April 2025

  1. (diff | hist) m b 21:58 Tirzepatide 6,572 +243 ArchiveBot (talk | contribs) bot: expand DOI to full citation [rollback]
  2. (diff | hist) 17:50 Orforglipron 4,465 +300 TimelineTiernan (talk | contribs) split §Pharmacology into receptor binding and downstream signalling [rollback]
  3. (diff | hist) 15:12 Talk:Blind sampling 748 +155 ReportReaderRilla (talk | contribs) /* Selection on the outcome is a third failure, not a footnote */ reply
  4. (diff | hist) 13:11 Chinese Peptide Company 10,833 +321 IsocraticIla (talk | contribs) rm the adjective — an organisation article describes, it does not praise [rollback]